主要目的：与注射用艾司奥美拉唑钠（Esomeprazole，ESO）相比，对消化性溃疡引起的上消化道出血且再出血风险为高危者经内镜下治疗后给予不同剂量给药方案的H008注射液以评价降低再出血风险的初步有效性。次要目的： 1) 与注射用ESO相比，对消化性溃疡引起的上消化道出血且再出血风险为高危者经内镜下治疗后给予不同剂量给药方案的H008注射液以评价本品的初步安全性； 2) 观察不同剂量H008注射液在消化性溃疡出血人群中的药代动力学特征，进一步评估本品在患者中的群体药代动力学特征。

开始日期2024-10-16

申办/合作机构

南京柯菲平盛辉制药有限公司

[+1]

ChiCTR2400089303 / Recruiting临床4期IIT

Comparison of Keverprazan-amoxicillin dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication: a prospective randomized controlled trial

开始日期2024-09-09

申办/合作机构-

ChiCTR2400087867 / Suspended临床4期IIT

Efficacy and safety of keverprazan in the treatment of non-erosive reflux disease:A randomized controlled trial

开始日期2024-09-01

申办/合作机构-

100 项与盐酸凯普拉生相关的临床结果

登录后查看更多信息

100 项与盐酸凯普拉生相关的转化医学

登录后查看更多信息

100 项与盐酸凯普拉生相关的专利（医药）

登录后查看更多信息

项与盐酸凯普拉生相关的文献（医药）

2024-11-01·Current gastroenterology reports

Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments

Review

作者: Scarpignato, Carmelo ; Hunt, Richard H

Abstract:

Purpose of the Review:

Acid suppression with proton pump inhibitors (PPIs) represents the standard of care in the treatment of acid-related diseases. However, despite their effectiveness, PPIs display some intrinsic limitations, which underlie the unmet clinical needs that have been identified over the past decades. The aims of this review are to summarize the current status and future development of the new class of antisecretory drugs (potassium-competitive acid blockers, P-CABs) that have recently been introduced into medical practice.

Recent Findings:

Over the past decades, clinical needs unmet by the current acid suppressants have been recognized, especially in the management of patients with GERD, Helicobacter pylori infection and NSAID-related peptic ulcer. The failure to address these needs is mainly due to their inability to achieve a consistent acid suppression in all patients and, particularly, to control nighttime acidity. It was then realized that an extended duration of acid suppression would exert additional benefits. The available data with P-CABs show that they are able to address these unmet clinical needs.

Summary:

Four different P-CABs (vonoprazan, tegoprazan, fexuprazan and keverprazan) are currently available. However, only two of them are approved outside Asia. Vonoprazan is available in North, Central and South America while tegoprazan is marketed only in Latin American countries. Two other compounds (namely linazapran glurate and zestaprazan) are presently under clinical development. While clinical trials on GERD have been performed with all P-CABs, only vonoprazan and tegoprazan have been investigated as components of Helicobacter pylori eradication regimens. The available data show that—in the above two clinical indications—P-CABs provide similar or better efficacy in comparison with PPIs. Their safety in the short-term overlaps that of PPIs, but data from long-term treatment are needed.

2024-11-01·INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

The efficacy of keverprazan-based quadruple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind, multicentre trial

Article

作者: Qiu, Rongyuan ; Li, Xing ; Liu, Chengxia ; Su, Dongxing ; Tan, Niandi ; Li, Fangfang ; Xia, Min ; Liu, Youli ; Jiao, Zhiyong ; Zhang, Zhe ; Su, Mei ; Chen, Huixin ; Zhang, Xiaomei ; Liao, Aijun ; Xiao, Weiming ; Xiao, Yinglian ; Wu, Hao ; Chen, Minhu ; Lan, Cheng

INTRODUCTION:

Keverprazan is a novel potassium-competitive acid blocker. The advantages of keverprazan as a potent acid suppressor in Helicobacter pylori eradication have not yet been demonstrated. The aim of this study was to evaluate the efficacy of keverprazan as a component of bismuth quadruple therapy in H. pylori treatment.

METHODS:

Adult patients with H. pylori infection were enrolled and randomised to take keverprazan (KEV group)- or esomeprazole (ESO group)-quadruple therapy. The regimens contained keverprazan 20 mg or esomeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1000 mg and bismuth potassium citrate 240 mg and were administered twice daily for 14 days. The primary endpoint was the H. pylori eradication rate at 4 weeks after treatment.

RESULTS:

The full analysis set showed that the H. pylori eradication rates were 87.8% (252/287) and 82.52% (236/286) for the KEV and ESO groups, respectively (difference: 5.29%; 95% confidence interval [CI]: -0.55-11.18). Keverprazan was superior to esomeprazole in terms of eradication rate in the per protocol set (P=0.0382). The eradication rates for patients resistant or non-resistant to clarithromycin were both numerically higher in the KEV group than the ESO group (83.45% vs. 76.98% for clarithromycin-resistance; 92.31% vs. 88.16% for clarithromycin-non-resistance). The incidence of adverse events was similar in the KEV and ESO groups (76.31% vs. 77.62%), with most adverse events (>90%) being mild in severity. No TEAEs led to death in either group.

CONCLUSIONS:

Keverprazan 20 mg twice daily, used as a component of bismuth quadruple therapy, provided effective H. pylori eradication and was non-inferior to an esomeprazole-based regimen.

2024-01-01·Therapeutic Advances in Gastroenterology

Potassium-competitive acid blockers and proton-pump inhibitors for healing of erosive esophagitis: a systematic review and network meta-analysis

Review

作者: Gao, Zhifeng ; Liu, Yin ; Hou, XiaoHua

Background::

Proton-pump inhibitors (PPIs) and potassium-competitive acid blockers (P-CABs) are recommended for erosive esophagitis (EE), with good safety and tolerance. However, it is unclear which is the best treatment option for EE.

Objectives::

This study aimed to evaluate the comparative efficacy of P-CABs and PPIs for healing EE patients, seeking an appropriate treatment choice in the 4- or 8-week treatment and standard or double dose.

Design::

A systematic review and network meta-analysis.

Data sources and methods::

Relevant databases were searched to collect randomized controlled trials of PPIs and P-CABs in the treatment of EE up to 31 May 2023. Studies on standard or double-dose PPIs or P-CABs which were published in English and assessed 4- or 8-week healing effects in EE were included. A network meta-analysis was performed to evaluate the efficacy of the treatments under the frequentist framework. Sensitivity and subgroup analyses of patients with different baseline EE were also conducted.

Results::

In all, 34 studies involving 25,054 patients and 9 PPIs, 6 P-CABs, or placebo treatment interventions were included. The pooled 4-week healing rate was significantly statistically lower than the pooled 8-week healing rate for most treatments. Besides, the higher healing rate of double-dose treatment than standard-dose treatment was not observed in the initial treatment of most drugs. The main analysis only included studies conducted for both patients with and without severe EE at baseline, and the proportion of severe EE included in the study was >10%, Keverprazan 20 mg qd ranked best with a surface under the cumulative ranking curve (SUCRA) value of 84.7, followed by Ilaprazole 10 mg qd with a SUCRA value of 82.0, for the healing rate at 8 weeks. Sensitivity analysis showed that the results were robust. Subgroup analysis showed that most P-CABs had higher healing rates than PPIs, particularly for patients with severe EE. And the healing rate of Keverprazan 20 mg qd at 8 weeks ranked best in the subgroup without or with severe EE at baseline.

Conclusion::

This study showed that an 8-week treatment seemed more effective than the 4-week treatment for healing EE patients. The healing effect of Keverprazan (20 mg qd) ranked best in 8-week treatment, for both severe and non-severe EE patients.

Trial registration::

The study protocol was registered with INPLASY (registration number INPLASY2023120053).

项与盐酸凯普拉生相关的新闻（医药）

2024-09-18

·复星医药

媒体聚焦 | 融入全球网络，复星医药探寻高质量发展“新”密码

以下内容来自新华网生物医药是上海市重点发展的三大先导产业之一，也是加快培育发展新质生产力的重要领域。发源于上海的复星医药，历经30年发展，如今已成为一家创新驱动的全球化医药健康产业集团。复星医药董事长吴以芳表示，今年上半年复星医药创新药品收入超37亿元，保持稳健增长。接下来，将继续在“创新、国际化、智能化、整合”的“组合拳”下，加大与高校、科研院所开展产学研合作，在早期阶段捕获源头创新产品，同时推动优质产品出海、推进全球同步开发，解决更多未被满足的健康需求，为创新发展添动能。瞄准未来健康领域持续“上新” 数据显示，2021年至2023年，上海生物医药产业规模从7617亿元提升至9337亿元，制造业产值由1712亿元增长到1860亿元。自2021年上海发布了《关于促进本市生物医药产业高质量发展的若干意见》以来，上海已有19款一类创新药和25款三类创新医疗器械获批上市，“首发引领”特征进一步凸显。今年上半年，上海生物医药制造业产值达到935亿元，较去年同期增加了37亿元。细胞与基因治疗、合成生物学、医疗机器人、高端医疗影像等前沿新赛道，正在加快孕育发展新动能。 “复星医药的创新方向与步伐与上海整体一致。”吴以芳说，今年上半年，公司核心制药业务实现营收146.77亿元，创新药业务在实体瘤、血液瘤、免疫炎症等领域取得了多项突破性进展。比如，复星旗下创新药公司复宏汉霖有一款治疗乳腺癌、胃癌的靶向药物“汉曲优”，是首个中、欧、美三地获批的中国国产单抗生物类似药，覆盖了全球48个国家，服务20多万名患者。这款药今年上半年实现销售收入14.743亿元，其中海外市场实现销售收入超6800万元，同比增长79.1%。在医疗器械方面，今年6月复星医药联营公司直观复星总部产业基地在上海张江国际医学园区落成启用。这是全球手术机器人龙头企业美国直观医疗公司在亚太地区最大的研发、生产和培训一体化基地，启用后将进一步加速达芬奇手术系统的国产化进程。吴以芳表示，自2006年进入中国市场以来，达芬奇手术机器人已在中国300多家医院落户，累计装机量超380台，服务逾54万名患者。随着基地的产能不断爬坡，在满足中国市场的基础上，也将服务周边地区更广泛的市场。从跟随式到源头式创新不断“升级” “早期我们在做创新的时候，更多是跟随战略，现在我们更强调转型升级，从跟随创新到源头创新，并敢于去在全球实现领先。”吴以芳说，尤其是针对重大疾病等未满足的健康需求，去开发真正能够提供临床最佳治疗价值的产品，锚定高价值创新，十分重要，也是很有意义。今年上半年，复星医药研发投入27.37亿元，其中研发费用为18.62亿元。制药业务研发投入24.06亿元，占制药业务收入的16.39%，其中研发费用为15.72亿元，占制药业务收入的10.71%。吴以芳提到，做创新，不仅是技术层面，还包括市场层面。以前更多是瞄准国内市场，现在从起点上考虑的就是全球市场，产品在研发设计阶段就是全球化的思路。 “相比过去更多把别人引进来，消化吸收，或者从商业上进行合作，现在，更多考虑怎么和国内的创新机构一起协同做好全球市场。”吴以芳说，包括高校、科研机构等，加强产学研紧密合作，把中国的创意推向全世界，现在的创新，可谓是焕然一新。上半年，复星医药自主研发、合作开发及许可引进的4个创新药/生物类似药共9项适应症进入上市前审批/关键临床阶段。制药板块专利申请达124项，其中包括美国专利申请2项、PCT申请8项，获得发明专利授权37项。除了已经拥有“汉曲优”在内的3款产品在海外获批上市，创新力满满的复宏汉霖还在布局50余个分子和14个研发平台，药物形式覆盖单抗、多抗、抗体偶联药物、融合蛋白、小分子药物等，创新蓄水池加速扩增，差异化创新优势进一步夯实。新阶段挖掘新增长潜力过去两年多，国内二级市场的不景气对生物医药行业的投资融环境造成了冲击，但是得益于国内产业基础和工程师、科学家的快速发展，国内药企出海的竞争力大幅加强，由此带动了BD交易（即业务发展交易，包括产品引进和对外授权，其中大部分围绕创新药进行）金额的大幅增加。这个拐点对于中国的生物医药行业非常重要。“BD交易额超过了IPO的融资额，在一定程度上，意味着中国的创新药获得了全球范围内的认可。”吴以芳指出，“内生+外延”两条腿走路，是复星医药一贯坚持的战略和成长发展路径。 “对于我们来讲，只要有好的机会，我们肯定也会积极去并购，包括国内以及国际市场，根据实际情况，可能会去做一些企业层面的并购，也有可能是一些产品层面的合作。”吴以芳说，通过开放式创新策略，加快创新成果的可及性。今年6月，复星医药获独家商业化许可的“苏可欣”于中国境内新增获批第二项适应症（用于治疗既往治疗反应不佳的成人慢性原发免疫性血小板减少症）。此外，包括双通道止吐药物“奥康泽”、我国自主研发的首款钾离子竞争性酸阻滞剂“倍稳”、长效重组人粒细胞集落刺激因子产品“珮金”及创新晶型的心衰和高血压治疗药物“一心坦”在内的已上市新品的入院及销售如期推进。吴以芳表示，围绕未被满足的临床需求，复星医药将通过自主研发、合作开发、许可引进、产业投资等多元化、多层次的合作模式，持续丰富创新产品管线，并不断聚焦差异化、高技术壁垒的产品研发。

生物类似药上市批准财报

2024-09-12

·国家药品监督管理局

国家药监局公布药品说明书适老化及无障碍改革试点名单（第三批）

根据《国家药监局关于发布药品说明书适老化及无障碍改革试点工作方案的公告》（2023年第142号），省级药品监管部门和国家药监局药品审评中心报送了参与试点的药品上市许可持有人和药品名单（第三批），现予公布。序号药品名称上市许可持有人1利伐沙班片天津力生制药股份有限公司2缬沙坦氨氯地平片（I）天津力生制药股份有限公司3呋塞米片天津力生制药股份有限公司4氢氯噻嗪片天津力生制药股份有限公司5盐酸普萘洛尔片天津力生制药股份有限公司6复方丹参滴丸天士力医药集团股份有限公司7养血清脑丸天士力医药集团股份有限公司8养血清脑颗粒天士力医药集团股份有限公司9盐酸二甲双胍片津药达仁堂集团股份有限公司新新制药厂10安宫牛黄丸津药达仁堂集团股份有限公司达仁堂制药厂11牛黄清心丸（局方）津药达仁堂集团股份有限公司达仁堂制药厂12大活络丸津药达仁堂集团股份有限公司达仁堂制药厂13清宫寿桃丸津药达仁堂集团股份有限公司达仁堂制药厂14包醛氧淀粉散天津太平洋制药有限公司15阿莫西林胶囊天津太平洋制药有限公司16包醛氧淀粉胶囊天津太平洋制药有限公司17吲达帕胺缓释胶囊天津太平洋制药有限公司18诺氟沙星胶囊天津太平洋制药有限公司19补肾通淋颗粒天津太平洋制药有限公司20牛磺酸颗粒天津太平洋制药有限公司21银黄颗粒天津太平洋制药有限公司22甲硝唑片天津太平洋制药有限公司23阿昔洛韦片天津太平洋制药有限公司24氨咖甘片天津太平洋制药有限公司25二羟丙茶碱片天津太平洋制药有限公司26非普拉宗片天津太平洋制药有限公司27格列本脲片天津太平洋制药有限公司28尼群地平片天津太平洋制药有限公司29羧甲司坦片天津太平洋制药有限公司30硝苯地平片天津太平洋制药有限公司31硝酸异山梨酯片天津太平洋制药有限公司32盐酸二甲双胍片天津太平洋制药有限公司33扎来普隆片天津太平洋制药有限公司34吲达帕胺片天津太平洋制药有限公司35利巴韦林片天津太平洋制药有限公司36复方磺胺甲噁唑片天津太平洋制药有限公司37谷维素片天津太平洋制药有限公司38醋酸氟轻松乳膏天津太平洋制药有限公司39丁酸氢化可的松乳膏天津太平洋制药有限公司40哈西奈德乳膏天津太平洋制药有限公司41健儿消食口服液天津和治药业集团有限公司42麦味地黄口服液天津和治药业集团有限公司43清喉咽合剂天津和治药业集团有限公司44清热解毒口服液天津和治药业集团有限公司45生脉饮天津和治药业集团有限公司46小儿咳喘灵口服液天津和治药业集团有限公司47小儿退热口服液天津和治药业集团有限公司48川贝止嗽合剂天津和治药业集团有限公司49消食健胃片天津和治药业集团有限公司50活力源片天津和治药业集团有限公司51四季感冒片天津和治药业集团有限公司52穿黄清热胶囊天津和治药业集团有限公司53血府逐瘀软胶囊天津和治药业集团有限公司54盐酸氟桂利嗪胶囊石家庄市华新药业有限责任公司55诺氟沙星胶囊石家庄市华新药业有限责任公司56盐酸二甲双胍缓释片石家庄市华新药业有限责任公司57吲达帕胺片石家庄市华新药业有限责任公司58盐酸左氧氟沙星片石家庄市华新药业有限责任公司59盐酸左氧氟沙星胶囊石家庄市华新药业有限责任公司60缬沙坦氨氯地平片（I）石家庄市华新药业有限责任公司61阿奇霉素干混悬剂石家庄市华新药业有限责任公司62阿奇霉素片石家庄市华新药业有限责任公司63硝酸甘油片石家庄市华新药业有限责任公司64伏格列波糖片石家庄市华新药业有限责任公司65头孢克肟干混悬剂石家庄市华新药业有限责任公司66菖麻熄风片黑龙江省济仁药业有限公司67参鹿茶黑龙江省济仁药业有限公司68前列闭尔通栓黑龙江省济仁药业有限公司69痹痛宁胶囊黑龙江乌苏里江制药有限公司哈尔滨分公司70氯诺昔康片黑龙江乌苏里江制药有限公司哈尔滨分公司71人参五味子颗粒黑龙江乌苏里江制药有限公司哈尔滨分公司72益脑宁片黑龙江新医圣制药有限责任公司73刺五加片黑龙江新医圣制药有限责任公司74宁神灵颗粒黑龙江新医圣制药有限责任公司75复方苦木消炎胶囊黑龙江新医圣制药有限责任公司76盐酸凯普拉生片江苏柯菲平医药股份有限公司77瑞维鲁胺片江苏恒瑞医药股份有限公司78羟乙磺酸达尔西利片江苏恒瑞医药股份有限公司79番泻叶颗粒江苏艾迪药业股份有限公司80米氮平片华裕（无锡）制药有限公司81氨氯地平阿托伐他汀钙片昆山龙灯瑞迪制药有限公司82雷米普利片昆山龙灯瑞迪制药有限公司83尼麦角林片昆山龙灯瑞迪制药有限公司84云南白药膏云南白药集团无锡药业有限公司85云南白药创可贴云南白药集团无锡药业有限公司86盐酸氨基葡萄糖片江苏正大清江制药有限公司87厄贝沙坦氢氯噻嗪片江苏中治制药有限公司88阿哌沙班片南京正大天晴制药有限公司89芦比前列酮软胶囊南京正大天晴制药有限公司90奥美沙坦酯氨氯地平片江苏诺泰澳赛诺生物制药股份有限公司91噻托溴铵粉雾剂正大天晴药业集团股份有限公司92伏立康唑分散片扬子江药业集团南京海陵药业有限公司93左乙拉西坦片扬子江药业集团南京海陵药业有限公司94黄蜀葵花总黄酮口腔贴片杭州康恩贝制药有限公司95肾宝合剂浙江康恩贝中药有限公司96复方玄驹胶囊浙江施强制药有限公司97山海丹颗粒浙江施强制药有限公司98枸橼酸氢钾钠颗粒浙江施强制药有限公司99小儿咳喘灵口服液杭州华润老桐君药业有限公司100葡萄糖酸锌口服溶液杭州华润老桐君药业有限公司101百令胶囊杭州中美华东制药有限公司102泮托拉唑钠肠溶胶囊杭州中美华东制药有限公司103阿卡波糖片杭州中美华东制药有限公司104氨氯地平阿托伐他汀钙片瀚晖制药有限公司105海博麦布片浙江海正药业股份有限公司106盐酸多奈哌齐片浙江华海药业股份有限公司107草酸艾司西酞普兰片浙江华海药业股份有限公司108左乙拉西坦片浙江华海药业股份有限公司109奥氮平口崩片浙江华海药业股份有限公司110奥美沙坦酯氢氯噻嗪片浙江华海药业股份有限公司111阿立哌唑口崩片浙江华海药业股份有限公司112缬沙坦氢氯噻嗪片浙江华海药业股份有限公司113他达拉非片浙江华海药业股份有限公司114盐酸贝那普利片浙江华海药业股份有限公司115多巴丝肼片浙江华海药业股份有限公司116盐酸舍曲林片浙江华海药业股份有限公司117盐酸帕罗西汀片浙江华海药业股份有限公司118普瑞巴林胶囊浙江华海药业股份有限公司119赛洛多辛胶囊浙江华海药业股份有限公司120甲磺酸雷沙吉兰片浙江华海药业股份有限公司121福辛普利钠片浙江华海药业股份有限公司122利培酮片浙江华海药业股份有限公司123阿立哌唑片浙江华海药业股份有限公司124磷酸西格列汀片浙江华海药业股份有限公司125西格列汀二甲双胍片(II)浙江华海药业股份有限公司126硝苯地平控释片浙江华海药业股份有限公司127富马酸卢帕他定片浙江华海药业股份有限公司128维格列汀片浙江华海药业股份有限公司129恩格列净片浙江华海药业股份有限公司130托吡酯片浙江华海药业股份有限公司131沙库巴曲缬沙坦钠片浙江昂利康制药股份有限公司132头孢克洛颗粒浙江昂利康制药股份有限公司133盐酸左氧氟沙星片浙江昂利康制药股份有限公司134替格瑞洛片浙江昂利康制药股份有限公司135琥珀酸普芦卡必利片浙江昂利康制药股份有限公司136磷酸西格列汀片浙江昂利康制药股份有限公司137头孢氨苄胶囊浙江昂利康制药股份有限公司138聚卡波非钙片浙江昂利康制药股份有限公司139泊沙康唑肠溶片江西山香药业有限公司140甲苯磺酸索拉非尼片江西山香药业有限公司141醋酸阿比特龙片江西山香药业有限公司142艾司奥美拉唑镁肠溶片江西山香药业有限公司143盐酸坦索罗辛缓释胶囊江西山香药业有限公司144雷贝拉唑钠肠溶片江西山香药业有限公司145甲磺酸多沙唑嗪缓释片江西山香药业有限公司146甲磺酸仑伐替尼胶囊江西山香药业有限公司147马来酸阿法替尼片江西山香药业有限公司148哌柏西利胶囊江西山香药业有限公司149狗皮膏江西地康药业有限公司150海马万应膏江西地康药业有限公司151十全大补酒南昌恒湖药酒有限责任公司152人参药酒南昌恒湖药酒有限责任公司153枸杞药酒南昌恒湖药酒有限责任公司154周公百岁酒南昌恒湖药酒有限责任公司155史国公药酒南昌恒湖药酒有限责任公司156苯磺酸左氨氯地平片江西施美药业股份有限公司157辣椒风湿膏江西吉安三力制药有限公司158风茄平喘膏江西吉安三力制药有限公司159愈裂贴膏江西吉安三力制药有限公司160冻疮未溃膏江西吉安三力制药有限公司161伤疖膏江西吉安三力制药有限公司162曲安奈德新霉素贴膏江西吉安三力制药有限公司163恩替卡韦片江西制药有限责任公司164氟哌啶醇片江西制药有限责任公司165阿托伐他汀钙片江西制药有限责任公司166化积口服液江西诚志永丰药业有限责任公司167桔贝合剂江西诚志永丰药业有限责任公司168麻杏甘石合剂江西诚志永丰药业有限责任公司169鲜竹沥江西诚志永丰药业有限责任公司170生脉饮（党参方）江西诚志永丰药业有限责任公司171五子衍宗口服液江西诚志永丰药业有限责任公司172健儿清解液江西诚志永丰药业有限责任公司173肾宝合剂江西诚志永丰药业有限责任公司174清热解毒口服液江西诚志永丰药业有限责任公司175生脉饮江西诚志永丰药业有限责任公司176桂附地黄口服液江西诚志永丰药业有限责任公司177金钱通淋口服液江西诚志永丰药业有限责任公司178金果饮江西诚志永丰药业有限责任公司179麦味地黄口服液江西诚志永丰药业有限责任公司180杞菊地黄口服液江西诚志永丰药业有限责任公司181玉屏风口服液江西诚志永丰药业有限责任公司182四逆汤江西诚志永丰药业有限责任公司183小青龙合剂江西诚志永丰药业有限责任公司184他达拉非片南昌立健药业有限公司185枸橼酸西地那非片南昌立健药业有限公司186脑安滴丸安徽雷允上药业有限公司187脑安胶囊安徽雷允上药业有限公司188复方苁蓉益智胶囊安徽雷允上药业有限公司189再造生血胶囊安徽雷允上药业有限公司190再造生血片安徽雷允上药业有限公司191益气养血口服液安徽雷允上药业有限公司192黄厚止泻滴丸安徽雷允上药业有限公司193卡马西平片宜昌人福药业有限责任公司194维生素B2片宜昌人福药业有限责任公司195维生素B6片宜昌人福药业有限责任公司196非布司他片宜昌人福药业有限责任公司197琥珀酸美托洛尔缓释片宜昌人福药业有限责任公司198盐酸二甲双胍缓释片宜昌人福药业有限责任公司199萘普生钠片宜昌人福药业有限责任公司200枸橼酸托法替布缓释片宜昌人福药业有限责任公司201氨酚羟考酮片宜昌人福药业有限责任公司202盐酸羟考酮缓释片宜昌人福药业有限责任公司203奥卡西平片武汉人福药业有限责任公司204安立生坦片武汉人福药业有限责任公司205ω-3脂肪酸乙酯90软胶囊人福普克药业（武汉）有限公司206布洛芬软胶囊人福普克药业（武汉）有限公司207度他雄胺软胶囊人福普克药业（武汉）有限公司208艾地骨化醇软胶囊人福普克药业（武汉）有限公司209乙磺酸尼达尼布软胶囊人福普克药业（武汉）有限公司210甲硝唑片远大医药（中国）有限公司211他达拉非片远大医药（中国）有限公司212酒石酸美托洛尔片远大医药（中国）有限公司213磷酸奥司他韦颗粒宜昌东阳光长江药业股份有限公司214磷酸奥司他韦胶囊宜昌东阳光长江药业股份有限公司215替米沙坦片宜昌东阳光长江药业股份有限公司216替格瑞洛片宜昌东阳光长江药业股份有限公司217非布司他片宜昌东阳光长江药业股份有限公司218氟康唑胶囊宜昌东阳光长江药业股份有限公司219西格列汀二甲双胍片II宜昌东阳光长江药业股份有限公司220西格列汀二甲双胍片Ⅲ宜昌东阳光长江药业股份有限公司221磷酸奥司他韦干混悬剂宜昌东阳光长江药业股份有限公司222克拉霉素片宜昌东阳光长江药业股份有限公司223苯甲酸阿格列汀片宜昌东阳光长江药业股份有限公司224琥珀酸索利那新片宜昌东阳光长江药业股份有限公司225阿哌沙班片宜昌东阳光长江药业股份有限公司226七蕊胃舒胶囊健民药业集团股份有限公司227虚汗停糖浆健民药业集团股份有限公司228小儿紫贝宣肺糖浆健民药业集团股份有限公司229盐酸托莫西汀口服溶液健民药业集团股份有限公司230拉考沙胺口服溶液健民药业集团股份有限公司231硫酸特布他林健民药业集团股份有限公司232马来酸噻吗洛尔滴眼液武汉新瑞医药科技有限公司233溴芬酸钠滴眼液武汉五景药业有限公司234阿莫西林胶囊湖南科伦制药有限公司235康复新液湖南科伦制药有限公司236泊沙康唑口服混悬液湖南科伦制药有限公司237血塞通片湖南绅泰春制药股份有限公司238六味地黄丸（浓缩丸）九芝堂股份有限公司239杞菊地黄丸（浓缩丸）九芝堂股份有限公司240驴胶补血颗粒九芝堂股份有限公司241蒙脱石散江右制药（常德）有限公司242复方金银花颗粒江右制药（常德）有限公司243风热感冒颗粒江右制药（常德）有限公司244前列癃闭通片江右制药（常德）有限公司245复方雪莲烧伤膏江右制药（常德）有限公司246四消丸江右制药（常德）有限公司247阿胶山东喜君康医药集团湘潭有限公司248苯磺酸氨氯地平片湖南千金协力药业有限公司249恩替卡韦分散片湖南千金协力药业有限公司250硫酸氨基葡萄糖胶囊湖南先施制药有限公司251古汉养生精口服液古汉中药有限公司252古汉养生精片古汉中药有限公司253枸橼酸西地那非片广州朗圣药业有限公司254他达拉非片广州朗圣药业有限公司255双氯芬酸钠缓释片国药集团致君（深圳）坪山制药有限公司256奥美沙坦酯氨氯地平片国药集团致君（深圳）坪山制药有限公司257依托考昔片国药集团致君（深圳）制药有限公司258左乙拉西坦片深圳信立泰药业股份有限公司259左乙拉西坦缓释片深圳信立泰药业股份有限公司260艾司奥美拉唑镁肠溶胶囊广东东阳光药业股份有限公司261奥氮平口崩片广东东阳光药业股份有限公司262富马酸喹硫平片广东东阳光药业股份有限公司263奥美沙坦酯片东莞市阳之康医药有限责任公司264盐酸莫西沙星片东莞市阳之康医药有限责任公司265阿立哌唑口崩片东莞市阳之康医药有限责任公司266阿立哌唑片东莞市阳之康医药有限责任公司267草酸艾司西酞普兰片东莞市阳之康医药有限责任公司268盐酸度洛西汀肠溶胶囊东莞市阳之康医药有限责任公司269厄贝沙坦胶囊珠海润都制药股份有限公司270厄贝沙坦氢氯噻嗪片珠海润都制药股份有限公司271复方丹参片广州白云山和记黄埔中药有限公司272脑栓通胶囊广东华南药业集团有限公司273盐酸安非他酮缓释片万特制药（海南）有限公司274阿立哌唑口服溶液万特制药（海南）有限公司275盐酸莫西沙星片重庆华邦制药有限公司276利伐沙班片重庆华邦制药有限公司277苯磺贝他斯汀片重庆华邦制药有限公司278萘替芬酮康唑乳膏重庆华邦制药有限公司279维A酸乳膏重庆华邦制药有限公司280盐酸左西替利嗪口服溶液重庆华邦制药有限公司281盐酸左西替利嗪片重庆华邦制药有限公司282阿伐斯汀胶囊重庆华邦制药有限公司283阿维A胶囊重庆华邦胜凯制药有限公司284异维A酸软胶囊重庆华邦胜凯制药有限公司285地奈德乳膏重庆华邦胜凯制药有限公司286甘桔冰梅片重庆华森制药股份有限公司287痛泻宁颗粒重庆华森制药股份有限公司288都梁软胶囊重庆华森制药股份有限公司289八味芪龙颗粒重庆华森制药股份有限公司290铝碳酸镁片重庆华森制药股份有限公司291铝碳酸镁咀嚼片重庆华森制药股份有限公司292奥美拉唑碳酸氢钠胶囊重庆华森制药股份有限公司293奥美沙坦酯氨氯地平片重庆华森制药股份有限公司294小金片太极集团重庆桐君阁药厂有限公司295苏合香丸太极集团重庆桐君阁药厂有限公司296沉香化气片太极集团重庆桐君阁药厂有限公司297强力天麻杜仲丸太极集团重庆桐君阁药厂有限公司298麻仁丸太极集团重庆桐君阁药厂有限公司299安宫牛黄丸太极集团重庆桐君阁药厂有限公司300还少丹（大蜜丸）太极集团重庆桐君阁药厂有限公司301还少丹太极集团重庆桐君阁药厂有限公司302归脾合剂太极集团重庆桐君阁药厂有限公司303桔贝合剂太极集团重庆桐君阁药厂有限公司304拨云退翳丸太极集团重庆桐君阁药厂有限公司305藿香正气口服液太极集团重庆涪陵制药厂有限公司306通天口服液太极集团重庆涪陵制药厂有限公司307急支糖浆太极集团重庆涪陵制药厂有限公司308急支颗粒太极集团重庆涪陵制药厂有限公司309补肾益寿胶囊太极集团重庆涪陵制药厂有限公司310丹参口服液太极集团重庆涪陵制药厂有限公司311盐酸文拉法辛片重庆药友制药有限责任公司312吲达帕胺片重庆药友制药有限责任公司313复方对乙酰氨基酚片（II）西南药业股份有限公司314布洛芬缓释片西南药业股份有限公司315维生素C咀嚼片西南药业股份有限公司316左氧氟沙星片四川新斯顿制药股份有限公司317塞来昔布胶囊四川新斯顿制药股份有限公司318盐酸氨基葡萄糖片四川新斯顿制药股份有限公司319苯酰甲硝唑分散片四川新斯顿制药股份有限公司320氯雷他定口腔崩解片四川新斯顿制药股份有限公司321盐酸美金刚片四川新斯顿制药股份有限公司322左氧氟沙星滴眼液四川美大康华康药业有限公司323盐酸莫西沙星滴眼液四川美大康华康药业有限公司324伏立康唑片四川美大康华康药业有限公司325来那度胺胶囊四川美大康华康药业有限公司326普乐安片云南白药集团股份有限公司327藿香正气胶囊云南白药集团股份有限公司328复方丹参片云南白药集团股份有限公司329六味地黄胶囊云南白药集团股份有限公司330关节止痛膏云南白药集团股份有限公司331伤湿止痛膏云南白药集团股份有限公司332麝香跌打风湿膏云南白药集团股份有限公司333一枝蒿伤湿祛痛膏云南白药集团股份有限公司334参苓健脾胃颗粒云南白药集团股份有限公司335宫血宁胶囊云南白药集团股份有限公司336痛舒胶囊云南白药集团股份有限公司337三七参蜂口服液云南白药集团股份有限公司338伤风停胶囊云南白药集团股份有限公司339丹溪玉屏风颗粒云南白药集团股份有限公司340风热感冒颗粒云南白药集团股份有限公司341四季感冒片云南白药集团股份有限公司342妇炎康片云南白药集团股份有限公司343痛舒片云南白药集团股份有限公司344消炎退热颗粒云南白药集团股份有限公司345板蓝根颗粒云南白药集团股份有限公司346热毒清片云南白药集团股份有限公司347玄麦甘桔颗粒云南白药集团股份有限公司348天紫红女金胶囊云南白药集团股份有限公司349小儿健脾平肝颗粒云南白药集团股份有限公司350小儿七星茶颗粒云南白药集团股份有限公司351止泻保童颗粒云南白药集团股份有限公司352泻痢消胶囊云南白药集团股份有限公司353生脉饮（党参方）云南白药集团股份有限公司354肿痛气雾剂云南白药集团股份有限公司355伤益气雾剂云南白药集团股份有限公司356利儿康口服液云南白药集团股份有限公司357陈香露白露片云南白药集团大理药业有限责任公司358气血康口服液云南白药集团文山七花有限责任公司359血塞通软胶囊昆药集团股份有限公司360血塞通片云南维和药业股份有限公司361血塞通胶囊云南维和药业股份有限公司362血塞通颗粒云南维和药业股份有限公司363盐酸莫西沙星片Bayer Vital GmbH364屈螺酮炔雌醇片Bayer Australia Ltd365琥珀酸索利那新片Astellas Pharma Europe B.V.366盐酸普拉克索片Boehringer Ingelheim International GmbH367达比加群酯胶囊Boehringer Ingelheim International GmbH368盐酸普拉克索缓释片Boehringer Ingelheim International GmbH369马来酸阿法替尼片Boehringer Ingelheim International GmbH

2024-08-28

·PRNewswire

Fosun Pharma Announces 2024 Interim Results

Breakthroughs for Innovative Products Going Overseas with Global Operation Capabilities Continuing to Strengthen SHANGHAI, Aug. 28, 2024 /PRNewswire/ -- On August 27, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH; 02196.HK), announced its operating performance for the first half of 2024 (the "Reporting Period"). During the Reporting Period, Fosun Pharma achieved revenue of RMB20.46 billion, an increase of 5.31% YoY after excluding COVID-related products. The net profit attributable to owners of the parent of the Group after deducting extraordinary gain or loss amounted to RMB1.3 billion. In the second quarter of 2024, the net profit attributable to owners of the parent of the Group after deducting extraordinary gain or loss was RMB646 million, a quarter-on-quarter increase of RMB37 million. As a global innovation-driven pharmaceutical and healthcare industry group, Fosun Pharma continuously advance its innovation transformation and the development and commercialization of innovative products. In the first half of 2024, Fosun Pharma's revenue from key innovative products in pharmaceuticals business grew steadily, exceeding RMB3.7 billion. In 2024, Fosun Pharma continued to boost operational efficiency and profitability, laying the foundation for long-term sustainable development. During the Reporting Period, the gross margin minus the selling and distribution expense ratio increased by 1.72 percentage points YoY; excluding the impact of newly acquired companies, the management expense decreased by about RMB0.2 billion. During the Reporting Period, Fosun Pharma ensured stable free cash flow through measures including optimizing operating cash flow, supply chain management, and controlling capital expenditures, achieving operating cash flow of RMB1.9 billion, a period-on-period increase of 5.36%, exceeding the growth of operating profit. In addition, the Group continued to optimize asset structure and improve asset efficiency. Since 2024, the cash inflow from asset disposals and the expected cash inflow from contracts signed by Fosun Pharma exceeded RMB2 billion in aggregate. Revenue from innovative products maintains steady growth, with a further focus on innovative drugs and high-value devices In the first half of 2024, Fosun Pharma further focused on innovative drugs and high-value devices. Four key innovative products with a total of 9 indications, independently developed and licensed-in by the Group, were approved for launch domestically and internationally. In addition to the key innovative products, Fosun Pharma also had 38 generic drug varieties approved for launch domestically and internationally. In the first half of 2024, Fosun Pharma's pharmaceutical manufacturing segment achieved revenue of RMB14.7 billion. The innovative drug business achieved breakthroughs in core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation, and realized multiple innovative achievements in hematologic tumors, breast cancer and lung cancer, benefiting patients worldwide. Han Si Zhuang (serplulimab injection), Fosun Pharma's first self-developed biopharmaceutical innovative drug, as well as the world's first anti-PD-1 monoclonal antibody (mAb) approved for the first-line treatment of small cell lung cancer (SCLC), was commercialized in the domestic market in March 2022. Up to now, it has been approved for 4 indications, broadly covering high-incidence tumours including lung cancer and gastrointestinal cancer, benefiting over 75,000 patients globally. Additionally, the 5th NDA of Han Si Zhuang for the first-line treatment of non-squamous non-small cell lung cancer (nsNSCLC) has been accepted by the National Medical Products Administration (NMPA) in China. During the Reporting Period, Fosun Pharma's self-developed biosimilar Han Da Yuan (adalimumab injection) received 4 new indications approval from the NMPA. It has now been approved for eight indications in China, covering all indications of originator adalimumab in China, providing more treatment options for adult and pediatric patients with autoimmune diseases. Fosun Pharma adheres to an open innovation strategy, and actively expands its pipelines through BD in addition to independent R&D. In June 2024, Su Ke Xin (avatrombopag malate tablets), which is exclusively commercialized by Fosun Pharma, received approval in Chinese mainland for a second indication for the treatment of adult patients with chronic primary immune thrombocytopenia (ITP) who have shown poor response to prior treatment, further benefiting ITP patients in China. Additionally, certain domestic innovative drugs licensed-in by the Group such as Bei Wen (keverprazan hydrochloride tablets) and Pei Jin (telpegfilgrastim injection), were officially included in the National Medical Drugs Catalogue in January 2024. This significantly enhanced the accessibility of drugs for relevant diseases within Chinese mainland and practically reduced the burdens of drugs on patients, aiming to improve the living and life quality of patients through regulated therapies. In the field of vaccines, Fosun Pharma has established an independent R&D system centered on two major technical platforms: bacterial vaccines and viral vaccines. In March 2024, the rabies vaccine (Vero cell) for human use (freeze dried), which is independently developed by the Group, has been approved for launch in Chinese mainland. The production line has also passed the GMP compliance inspection. Research progress on various pipelines develops rapidly to secure innovative development To meet the unmet clinical needs, through diversified and multi-level cooperation models such as independent R&D, co-development, license-in and industrial investment, Fosun Pharma continues to enrich its innovative product pipeline and focus on differentiated product R&D with high-tech barriers, to continuously enhance the value of its pipeline. In the first half of 2024, Fosun Pharma's total R&D expenditure amounted to RMB2.7 billion, with R&D expenses totaling RMB1.9 billion. The R&D expenditure in the pharmaceutical manufacturing segment amounted to RMB2.4 billion, accounting for 16.4% of the segment's revenue. In particular, R&D expenses were RMB1.6 billion, accounting for 10.7% of the segment's revenue. In the first half of 2024, 4 innovative drugs/biosimilars with a total of 9 indications independently developed, co-developed and licensed-in by the Group had entered the pre-launch approval/critical clinical stage. The pharmaceutical manufacturing segment of the Group submitted 124 patent applications, including 2 American patents applications, 8 PCT applications, and the Group has obtained 37 licensed invention patents authorization. During the Reporting Period, the New Drug Application (NDA) of self-developed selective MEK1/2 inhibitor (project code: FCN-159) for two indications was accepted by NMPA in May and June 2024, both of which were included in the priority review procedure. The Marketing Authorization Application (MAAs) for five indications of the self-developed denosumab biosimilar HLX14 (recombinant anti-RANKL fully human monoclonal antibody injection) was accepted by the European Medicines Agency (EMA). Additionally, during the Reporting Period, the Phase 3 clinical trials for its self-developed Han Si Zhuang (serplulimab injection), in combination with bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer (mCRC) patients, had commenced in the Chinese mainland. The combination dosing of OP0595 and cefepime or aztreonam, developed by Fosun Pharma in collaboration with Meiji Seika Pharma Co., Ltd., for the treatment of adults infected by aerobic gram-negative bacteria with limited options, had commenced two phase III clinical trials in China. During the Reporting Period, clinical data from multiple pipeline products and marketed products of Fosun Pharma were presented at global industry conferences, including the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), and the European Hematology Association (EHA), further demonstrating the Group's innovative R&D capabilities on the international stage. In addition to independent R&D, Fosun Pharma actively practices an open R&D model, engaging in the incubation and investment of R&D projects through initiatives such as the establishment and management of industrial funds, ensuring the sustainability of its innovation pipeline. During the reporting period, Fosun Pharma successfully completed the establishment and filing of Shenzhen Biopharma Industrial Fund with fundraising size of RMB5.0 billion Continues to enhance global operation capabilities and gains international recognition for innovative products Fosun Pharma continues to uphold the internationalization strategy in multiple dimensions, such as innovative R&D, two-way license, production and operations as well as commercialization to enhance operational efficiency and strengthen global market layout while covering major overseas markets, including the United States, Europe, Africa, India, and Southeast Asia. As at the end of the Reporting Period, the Group had formed an overseas commercialization team of approximately 1,000 employees. For the first half of 2024, overseas revenue reached RMB5.5 billion, an increase of 15.13% YoY, accounting for 26.93% of total revenue. During the Reporting Period, Fosun Pharma's self-developed Han Qu You (trastuzumab injection, trade name: HERCESSI™ in the U.S., Zercepac® in Europe) received the U.S. FDA approval for three indications covering the treatment of breast cancer and gastric cancer, becoming the first domestic biosimilar approved for launch in China, the EU and the United States. Additionally, through collaboration with global renowned pharmaceutical companies, Fosun Pharma has established a presence in Europe, the United States, Canada, and numerous emerging markets. Up to date, Han Qu You has been approved in 48 countries and regions, benefiting 200,000+ patients, bringing affordable and high-quality treatment options to breast cancer and gastric cancer patients worldwide. Self-developed biopharmaceutical innovative drug of Fosun Pharma, Serplulimab Injection (anti-PD-1 monoclonal antibody, Chinese trade name: Han Si Zhuang) completed the first international shipment in January 2024, making it the first Chinese anti-PD-1 mAb approved for launch in Southeast Asia. The marketing authorization application (MAA) of Han Si Zhuang has been accepted in March 2023 and its head-to-head bridging trial comparing to first-line standard of care with Atezolizumab for extensive-stage small cell lung cancer (ES-SCLC) had entered clinical enrollment stage in the United States. At the same time, Fosun Pharma has established an innovative drug team in the United States to advance the commercialization of Serplulimab Injection. Fosun Pharma actively introduces leading international technologies and products into the Chinese market to benefit more patients. During the Reporting Period, the Headquarters Industrial Base of the joint venture Intuitive Fosun officially opened and was put into operation in Shanghai Zhangjiang International Medical Park. The base integrates R&D, production and training, and its operation will further accelerate the localization process of the Da Vinci Surgical System. As at the end of June 2024, the accumulated total installation volume of the Da Vinci Surgical Robot in Chinese mainland and Hong Kong S.A.R.and Macau S.A.R. was over 380 in more than 300 hospitals. More than 540,000 patients had benefited from the Da Vinci Surgical Robot's precise treatment and returned to normal life. During the Reporting Period, Fosun Pharma's joint venture with Insightec, Fosun Insightec, made steady progress in the commercialization, clinical application and research of magnetic resonance-guided focused ultrasound treatment system for neurological diseases (MRgFus brain therapy system) in Chinese mainland, Hong Kong S.A.R and Macao S.A.R.. As a global pharmaceutical and healthcare industry group, Fosun Pharma continues to promote the building of production system with international quality standard, with its quality management system and production capabilities recognized by leading international certification authorities, laying a solid foundation for the overseas distribution of preparations. As at the end of the Reporting Period, all production lines of the domestic subsidiaries under the pharmaceutical manufacturing segment of the Group obtained domestic GMP certifications and 10 production lines had passed GMP certification in major regulatory markets such as the U.S. and the EU. "Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma consistently focuses on unmet clinical needs, prioritizes innovative R&D, adheres to technology-driven and product-driven approach, and strengthens global operation capabilities, ensuring steady and sustainable development." Wu Yifang, Chairman of Fosun Pharma, said, "Looking forward, Fosun Pharma's internal operation will be further improved in quality and efficiency, continuing to enhance its leading position in hematologic tumors, breast cancer, lung cancer and other fields while expanding footprint in immunity inflammation, chronic diseases and central nervous system. We will also intensify industry-university-research strategic cooperation with world-class universities and research institutions to capture innovative products at an early stage. At the same time, we will actively promote the overseas export of high-quality products and promote global simultaneous development, aiming to become the global leading integrator of pharmaceutical and healthcare innovation." About Fosun Pharma Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business. Fosun Pharma is patient-centered and unmet clinical needs-oriented. Through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and industrial investment, the company continues to enrich its innovative product pipeline and focus on differentiated product R&D with high-tech barriers, to continuously enhance the value of its pipeline. Fosun Pharma's innovative products focus on core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation. It also strengthens core technology platforms such as antibodies/ADC, cell therapy, and small molecules. Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma adheres to the business philosophy of "Innovation for Good Health", continues to promote innovative transformation, actively deploys internationalization, strengthens business focus by product lines, promotes integrated operations and efficiency improvement, and is dedicated to being the global leading integrator of pharmaceutical and healthcare innovation. For more information, please visit our official website: SOURCE Fosun Pharma

上市批准临床3期

100 项与盐酸凯普拉生相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
反流性食管炎	中国	江苏柯菲平医药股份有限公司	2023-02-15
十二指肠溃疡	中国	江苏柯菲平医药股份有限公司	2023-02-14

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
幽门螺杆菌感染	临床3期	中国	江苏柯菲平医药股份有限公司	2022-04-17
幽门螺杆菌感染	临床3期	中国	南京柯菲平盛辉制药有限公司	2022-04-17
消化性溃疡出血	临床2期	中国	江苏柯菲平医药股份有限公司	2024-10-16
消化性溃疡出血	临床2期	中国	南京柯菲平盛辉制药有限公司	2024-10-16
糜烂性食管炎	临床1期	美国	江苏柯菲平医药股份有限公司	2021-06-24
早期胃癌	临床1期	中国	南京柯菲平盛辉制药有限公司	2018-09-03
早期胃癌	临床1期	中国	江苏柯菲平医药股份有限公司	2018-09-03
幽门螺杆菌相关性胃炎	临床1期	中国	南京柯菲平盛辉制药有限公司	2018-09-03
幽门螺杆菌相关性胃炎	临床1期	中国	江苏柯菲平医药股份有限公司	2018-09-03
胃MALT淋巴瘤	临床1期	中国	南京柯菲平盛辉制药有限公司	2018-09-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed 人工标引	临床3期	十二指肠溃疡	360	Keverprazan 20 mg	築繭醖窪範壓壓醖憲築(鏇壓鏇夢壓製製蓋醖鹽) = 醖齋艱製淵淵願廠鏇糧選簾憲壓糧艱遞蓋積鑰 (築壓蓋顧齋鏇鏇簾淵簾 ) 更多	非劣	2023-07-01
				Lansoprazole 30 mg	築繭醖窪範壓壓醖憲築(鏇壓鏇夢壓製製蓋醖鹽) = 鬱醖觸鏇衊遞壓繭獵憲選簾憲壓糧艱遞蓋積鑰 (築壓蓋顧齋鏇鏇簾淵簾 ) 更多
Pubmed 人工标引	临床3期	糜烂性食管炎	238	Keverprazan 20 mg	糧鹽構繭鏇淵築糧蓋憲(淵膚觸顧壓憲築遞糧製) = 餘願構膚餘蓋醖積顧網遞齋選觸壓鑰蓋範願構 (鏇餘繭鑰鏇壓糧醖鹽鬱 ) 更多	非劣	2022-05-03
				Lansoprazole 30 mg	糧鹽構繭鏇淵築糧蓋憲(淵膚觸顧壓憲築遞糧製) = 選顧構齋鬱選鹹願範獵遞齋選觸壓鑰蓋範願構 (鏇餘繭鑰鏇壓糧醖鹽鬱 ) 更多